Key takeaways
Semaglutide dosing is not a fixed prescription. But rather, it is a progressive clinical protocol, and how it is structured matters as much as the medication itself.
This guide covers how semaglutide dosing for weight loss works from the first injection through the maintenance phase, including the 2026 dosing changes, a unit-based chart for compounded versions, and the clinical reasoning behind why doses increase gradually over time.
At InjectCo, our licensed nurse providers have guided thousands of Texas patients through personalized weight loss programs across nine clinics. What you read here reflects both the clinical evidence and what we observe directly in practice. Consult your medical provider before starting any weight loss program.
Semaglutide dosing for weight loss follows a titration model: doses start low and increase at defined intervals to allow the body to adjust while minimizing side effects. The medication belongs to a class called GLP-1 receptor agonists, which mimic a naturally occurring hormone that regulates appetite, digestion, and blood sugar. At the correct dose, it reduces caloric intake by signaling fullness earlier and slowing gastric emptying.
The titration schedule exists for a clinical reason. Jumping to a higher dose too quickly significantly increases the risk of nausea, vomiting, and gastrointestinal discomfort. A titration tolerability study (PMC) found that patients who followed the standard titration protocol had meaningfully better tolerability outcomes than those who escalated faster. Going slow is not a drawback of this treatment; it is the mechanism that makes it sustainable.
One patient we saw recently at our Fort Worth clinic, a woman in her mid-40s, came in frustrated. She had tried other programs that moved her dose up too quickly and spent two months feeling sick rather than making progress. What we told her is what we tell everyone: the goal is the lowest dose that produces steady, consistent results with the fewest side effects. That is how the semaglutide weight loss program in Fort Worth is designed to work.
The semaglutide starting dose for weight loss is 0.25 mg once weekly for the first four weeks. This initial dose is not intended to produce weight loss. It is a tolerability phase: the body learns to process the medication without the side effects that accompany higher doses.
After four weeks at 0.25 mg, doses increase in steps every four weeks, following the pattern below. The standard injection schedule reaches a target maintenance dose of 2.4 mg after approximately 16 weeks. As of March 2026, a higher dose of 7.2 mg per week has been approved for eligible patients in the U.S. (see the maximum dose section below).
Here’s a full semaglutide dosage chart in units:
| Weeks | Dose (mg/week) | Clinical Purpose |
|---|---|---|
| 1 to 4 | 0.25 mg | Tolerability phase; body adapts to GLP-1 signaling |
| 5 to 8 | 0.50 mg | Early appetite suppression begins for most patients |
| 9 to 12 | 1.0 mg | Active weight loss phase; most patients see consistent results |
| 13 to 16 | 1.7 mg | Dose escalation toward target; continue if well tolerated |
| Week 17 onward | 2.4 mg | Standard maintenance dose; sustained weight management |
| Extended (eligible) | Up to 7.2 mg | New FDA-approved maximum as of March 2026; physician evaluation required |
Providers may pause at any step if side effects require more adjustment time. Not every patient needs to reach the highest dose. The goal is always the lowest effective dose for each individual, not a specific number.
Compounded semaglutide is not dosed in milligrams at the syringe. It is dosed in units, which depends on the concentration of the vial your provider or pharmacy has prepared. This distinction matters, as two patients prescribed the same dose in milligrams may draw different volumes if their vials have different concentrations.
The two most common vial concentrations for compounded semaglutide are 2.5 mg/mL and 5 mg/mL. The chart below shows how standard weekly doses convert to units on a U-100 insulin syringe for each concentration.
IMPORTANT: This chart is for general education only. Actual dosing units depend on the specific concentration and formulation of your compounded vial. Always confirm your prescribed volume with your licensed provider.
| Weekly Dose (mg) | 2.5 mg/mL Vial (units) | 5 mg/mL Vial (units) | Phase |
|---|---|---|---|
| 0.25 mg | 10 units | 5 units | Week 1 to 4: Tolerability phase) |
| 0.50 mg | 20 units | 10 units | Week 5 to 8: Early suppression |
| 1.0 mg | 40 units | 20 units | Week 9 to 12: Active weight loss |
| 1.7 mg | 68 units | 34 units | Week 13 to 16: Escalation phase |
| 2.4 mg | 96 units | 48 units | Week 17+:Standard maintenance |
These conversions assume a standard U-100 insulin syringe (1 unit = 0.01 mL). If your provider prescribes a different syringe type or vial concentration, ask for a unit-conversion guide specific to your formulation. Never guess.
Compounded medications are not FDA-approved. They are prepared by licensed compounding pharmacies and prescribed by a licensed provider as part of a supervised clinical program. Most patients also want to know more about compounded vs brand-name semaglutide differences based on their personal weight loss goals.
Oral semaglutide for weight loss works differently from the injectable form. The standard oral dosing protocol starts at 3 mg once daily for the first 30 days, then increases to 7 mg daily, with a maximum labeled dose of 14 mg daily. The tablet must be taken on an empty stomach with a small amount of plain water at least 30 minutes before any food, drink, or other medications to allow proper absorption. InjectCo also offers an oral vs injectable semaglutide comparison.
Clinical studies comparing oral and injectable forms consistently show that the injectable version produces greater weight loss outcomes for most patients. The oral form can be a reasonable option for patients who prefer not to self-inject, but clinical expectations should be calibrated accordingly. Your provider will walk you through which format aligns best with your goals, medical history, and lifestyle.
A higher dose of semaglutide does not automatically mean more weight loss, as the dose-response relationship is more nuanced than that. The primary reason doses increase is to move from a tolerability phase into a therapeutically active range, not simply to intensify the effect.
Research shows that patients who reach the 2.4 mg weekly maintenance level see greater average weight reduction compared to those who remain at 1 mg or below. However, the most important clinical signal is not the dose number itself, but rather, it is whether your body is responding, tolerating the medication, and continuing to progress. A patient losing weight steadily at 1.0 mg weekly has no clinical reason to escalate.
Providers increase the dose when one of three conditions is met: the side effects at the current dose have become manageable, weight loss has plateaued below the patient’s goal, or enough time has passed under the titration protocol to safely advance. The decision is always made in consultation with the provider, not by the patient independently.
Increasing the dose on your own, or more frequently than prescribed, raises the risk of severe gastrointestinal side effects and does not accelerate your long-term results. If you feel your current dose is not working, the right step is to discuss it with your provider at your next scheduled follow-up.
InjectCo’s physician-supervised weight loss program in Plano, TX, includes progress tracking, dose adjustments, and ongoing monitoring as your body responds to the medication.
Once patients reach 2.4 mg per week and have stabilized there for several months, the focus shifts from escalation to consistency. This is the maintenance phase: the dose stays the same while the body continues to respond to the medication’s appetite-regulating and metabolic effects. For semaglutide every-other-week dosing, see what the evidence says.
Many patients ask whether they can stay on a lower maintenance dose rather than the full 2.4 mg. The answer depends on how your body is responding. Some patients achieve their goal weight at 1.0 mg or 1.7 mg and remain there with their provider’s agreement. That is a clinically reasonable outcome, and it carries a better side effect profile for patients who are sensitive to higher doses.
One question that comes up often is whether semaglutide can be taken every other week for maintenance once the goal weight is reached. The clinical evidence does not support biweekly dosing as a substitute for weekly administration. Spacing injections out increases the risk of appetite returning between doses and weight regain over time. Discuss any changes to your dosing frequency directly with your provider before making them.
The maximum dose of semaglutide approved for weight management in the U.S. is now 7.2 mg per week as of March 2026, following FDA review of the STEP UP trial. This replaces the previous 2.4 mg ceiling for eligible adult patients with obesity or overweight and a weight-related condition.
The STEP UP Phase 3b clinical trial, published in The Lancet Diabetes and Endocrinology in 2025, enrolled over 1,400 adults with obesity and without diabetes. Patients on the 7.2 mg weekly dose achieved an average weight loss of 20.7% of starting body weight over 72 weeks, compared to 17.5% at the standard 2.4 mg dose. Roughly one in three participants reached 25% or more weight loss at the higher dose.
Not all patients will need or qualify for the 7.2 mg level. The higher dose carries a higher incidence of gastrointestinal side effects, particularly nausea and vomiting, and a newly identified effect: dysaesthesia (tingling or burning sensations affecting the skin) occurred in approximately 23% of patients on 7.2 mg versus 6% at 2.4 mg. For the majority of patients, reaching and maintaining the 2.4 mg level still provides substantial, clinically significant weight loss.
The 7.2 mg dose requires physician evaluation and is not a default starting point. If you are currently in a weight loss program and want to discuss whether the higher dose is appropriate for your situation, bring it up at your next follow-up appointment.
This program may not be suitable for everyone. Consult your medical provider before starting or adjusting any weight loss program. Medications are prescribed at the discretion of a licensed provider.
A physician-guided semaglutide program may be appropriate for adults who meet the following criteria. Disclaimer: This is a general overview, not a substitute for a clinical evaluation. For medical-related issues, consult with the appropriate healthcare provider.
GLP-1 weight loss programs work best when combined with nutritional support, activity guidance, and ongoing medical oversight. For physician-supervised weight loss in Dallas, TX, a licensed provider will assess your full health history, current medications, and goals before determining whether semaglutide is right for your program.
At InjectCo, weight loss treatment begins with a physician evaluation. Our licensed nurse providers conduct a thorough intake covering your health history, current medications, prior weight loss attempts, and goals before any clinical recommendation is made. Medication is prescribed at provider discretion and is one possible component of a larger protocol.
Kiara DeWitt, our founder and a BSN, RN, CPN with a background in neurosurgery and pediatric nursing at Cook Children’s Hospital, built InjectCo around a simple belief: that patients deserve a clinical environment where they feel heard and where treatment decisions are made on evidence, not revenue targets.
We operate across nine Texas locations including Fort Worth, Plano, Dallas, Colleyville, the Woodlands, and Austin. Most patients start their semaglutide weight loss program at InjectCo during their first visit. Follow-ups are conducted on a schedule that fits your dosing timeline, and our providers adjust your protocol based on your actual progress, not a predetermined pace.
Semaglutide dosing for weight loss is a progressive process. It starts with a low tolerability dose, increases through a structured titration schedule, and settles into a maintenance level that varies by patient. The chart numbers in this guide are reference points, not prescriptions. What matters is how your body is responding and what your provider recommends based on that response.
With the 2026 expansion to a 7.2 mg maximum for eligible patients, more options exist than ever before. But the most effective dose is still the one your provider designs for your specific situation, monitored over time by someone who knows your health history.
Ready to find out if a physician-guided weight loss program is right for you? Schedule a free consultation with InjectCo and let our licensed providers walk you through your options.
Results may vary. This program may not be suitable for everyone. Consult your medical provider before starting any weight loss program.
The standard starting dose of semaglutide for weight loss is 0.25 mg once weekly for the first four weeks. This low initial dose is a tolerability phase, as it allows the body to adjust to GLP-1 signaling and reduces the risk of nausea and other gastrointestinal side effects before doses are increased.
As of March 2026, the FDA approved a maximum weekly dose of 7.2 mg for eligible adults. Prior to this approval, the standard ceiling was 2.4 mg per week. Most patients achieve their weight loss goals at the 2.4 mg maintenance level. The 7.2 mg dose is reserved for eligible patients under physician evaluation and carries a higher rate of gastrointestinal side effects.
Under the standard titration schedule, most patients reach the 2.4 mg maintenance dose after approximately 16 to 17 weeks of weekly injections. The schedule increases the dose every four weeks, starting from 0.25 mg. Providers may slow the escalation if side effects require more adjustment time.
Compounded semaglutide is administered using a U-100 insulin syringe and measured in units rather than milligrams. The unit dose depends on the concentration of the vial. A 2.5 mg/mL vial requires 10 units for a 0.25 mg dose; a 5 mg/mL vial requires only 5 units for the same dose. Always confirm the correct volume with your prescribing provider.
Not automatically. A higher dose of semaglutide increases the likelihood of reaching a therapeutically active level, and research shows greater average weight loss at 2.4 mg versus 1.0 mg. However, many patients achieve their goals without needing the maximum dose. The best dose is the lowest one that produces consistent results with manageable side effects, as determined by your provider.
The dose increases over time to move from a tolerability phase into a therapeutically active range. Starting at 0.25 mg allows the body to adapt to GLP-1 signaling. Dose escalation proceeds in steps to minimize nausea and gastrointestinal side effects while building toward the target maintenance dose. The increase schedule is based on tolerability, not on maximizing the dose as quickly as possible.
Semaglutide is approved for once-weekly administration. Taking it every other week is not supported by clinical evidence and may allow appetite to return between doses, increasing the risk of weight regain. If you want to reduce your dosing frequency as part of a maintenance strategy, discuss this with your provider before making any changes.
For a common 5 mg/mL compounded vial on a U-100 syringe: 5 units for 0.25 mg, 10 units for 0.5 mg, 20 units for 1.0 mg, 34 units for 1.7 mg, and 48 units for 2.4 mg. For a 2.5 mg/mL vial, those amounts double. Confirm your prescribed volume with your provider before each injection.
If you miss a dose, contact your provider for guidance specific to your schedule. Do not double the next dose. If the missed injection was within five days, your provider may advise taking it as soon as possible. If more than five days have passed, the general guidance is to skip the missed dose and resume the following week. Never adjust your protocol without provider instruction.
No. Oral semaglutide is taken daily in milligram tablets, starting at 3 mg once daily, then 7 mg, with a maximum labeled dose of 14 mg daily. Injectable semaglutide is administered once weekly starting at 0.25 mg per week. The two forms are not interchangeable in dose or schedule.
The clearest sign that your semaglutide dose is effective is reduced appetite and consistent, measurable weight loss over several weeks. Most patients notice appetite suppression beginning around weeks 4 to 8, as the dose moves above the tolerability phase. If you are not seeing results at your current dose after six to eight weeks, discuss dose escalation with your provider at your next follow-up.
InjectCo’s physician-guided weight loss program is available to adults across nine Texas locations and online for patients in eligible states. Eligibility is assessed individually by a licensed provider and typically includes a BMI of 30 or higher, or 27 or higher with a weight-related condition. A free virtual consultation is the first step.
